Lung and head/neck cancers exhibit mutation-stabilized Nrf2 enhancing ROS tolerance [81], while breast cancer utilizes Ras/MAPK-dependent Nrf2 activation [82]. This evidence concerns the gene NFE2L2 and breast cancer.